BackAltimmune Overview

Altimmune Receivables

Latest receivables for ALT: $1.7M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$1.67M
228.40% YoYΔ $1.16M vs prior year quarter

Peer average

Loading

Altimmune Receivables History

Loading

Altimmune vs. peers: Receivables Comparison

Loading

Altimmune Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Altimmune (ALT) FAQ

As of the most recent data (March 2026), ALT shows a receivables of $1.7M. That compares with $510K in the prior-year period — up 228.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ALT's receivables is now $1.7M (was $510K) — a 228.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Altimmune is outperforming or lagging.

Tracking ALT's receivables over time shows whether Altimmune is scaling, shrinking, or reshaping that part of the business. The current reading is $1.7M That compares with $510K in the prior-year period — up 228.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Altimmune's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $1.7M) with ownership activity and broader fundamentals.

Altimmune's receivables is $1.7M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.